EANM

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

United Imaging Healthcare debuts Next-Generation PET/CT Systems, the uMI Panorama Family, and the Integrated Molecular Technology Platform at EANM

Retrieved on: 
Thursday, September 21, 2023
Yale University, CE, IPO, University of California, Davis, NX, University, Moses Austin, MI, NEMA, Peking Union Medical College Hospital, EANM, BRAIN, Deep learning, NCI-designated Cancer Center, PET, Brain, Research, Nuclear medicine, Radiopharmaceutical, Washington University in St. Louis, Gold standard, Umi, Huntsman Cancer Institute, Radiation, European Association of Nuclear Medicine, UC, Patient, Molecular imaging, Fudan University, DOI, PET/CT, Artificial intelligence, AdventHealth Celebration, Panorama, Neoplasm, FDA, FOV, AI, Zhongshan Hospital, Medical imaging

VIENNA, Sept. 21, 2023 /PRNewswire/ -- United Imaging Healthcare, a global leader in advanced medical imaging and radiotherapy equipment, introduces its next-generation PET/CT systems, the uMI Panorama™, and the integrated molecular technology platform named uExcel, at the European Association of Nuclear Medicine (EANM) 2023 annual meeting taking place from September 9-12 in Vienna, Austria. As the sponsor of the "EANM Young Authors' Award" and "EANM Technologist Award" this year, United Imaging is playing a significant role in driving innovation in the field of molecular imaging and nuclear medicine on a global scale.

Key Points: 
  • The new wide-bore uMI Panorama is a family of products that includes the uMI Panorama, the uMI Panorama GS, and the NeuroEXPLORER.
  • The uMI Panorama GS, deriving its name from the term "Gold Standard", was born to set the gold standard in molecular imaging and revolutionize whole-body PET imaging.
  • In tandem with uMI Panorama, the uExcel, is an advanced molecular imaging technology platform meticulously integrated with both hardware and software components.
  • (Note: The uMI Panorama and the uMI Panorama GS are CE pending, not commercially available yet.

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Retrieved on: 
Wednesday, September 13, 2023
DARPin, Partnership, AACR, Therapy, EANM, Half-life, RDT, Nuclear medicine, Delta, Radiation, DLL3, European Association of Nuclear Medicine, Novartis, Molecular Partners, Engineering, Kidney, Neoplasm, Radio, Pharmaceutical industry, Vaccine, CONCORD

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .

Key Points: 
  • These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .
  • The data show the ability of Molecular Partners to substantially increase tumor uptake of RDT candidates through an adjustment of systemic half-life, achieved by binding to the common blood protein serum albumin.
  • With today’s data we show that tuning of half-life can substantially impact the tumor uptake of our Radio DARPins,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023
Pheochromocytoma, DOTATATE, NETS, MBBS, EANM, TAT, Thyroid cancer, Quality of life, DNB, Nuclear medicine, Paraganglioma, PET-CT, Șaeș, Non-small-cell lung cancer, MDS, Hair, Targeted molecular therapy for neuroblastoma, CATX, Patient, Standard of care, Syndrome, Molina Healthcare, FMRI, European Association for the Study of the Liver, Therapy, NYSE, PRRT, Meningioma, Safety, Fatigue, Pharmaceutical industry

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, September 11, 2023
Survival rate, Glomus tumor, NETS, Radiation, Index, Probability, Metastasis, EANM, SCID, Neoplasm, Survival, WWIC, Toxicity, Research, Nuclear medicine, Neuroendocrine cell, Congress, Korea Military Academy, Korea, CATX, WMIC, Mouse, MTD, European Association for the Study of the Liver, Therapy, NYSE, Human, Pharmaceutical industry, Medical imaging

SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the World Molecular Imaging Congress (WMIC) 2023, held on September 5-9, 2023, in Prague, Czech Republic, and the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from September 9-13, 2023.

Key Points: 
  • Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs).
  • The study was carried out by Dr. Dongyoul Lee, an assistant professor at the Korea Military Academy.
  • The dose depositions in tumor and normal organs were estimated based on 203Pb biodistribution data.
  • In addition, tumor progression, survival rates, and body weight changes over a 120-day period were assessed, and favorable radiochemical characteristics were observed.

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Retrieved on: 
Thursday, September 7, 2023
Carcinoma, Maintenance, EANM, PET, Cell, Immunotherapy, Doctor of Philosophy, SCLC, Neoplasm, Patient, Cancer, IB, Diagnosis, SST2, European Association of Urology, Therapy, Recurrence, Safety, Disease, Pharmaceutical industry, Vaccine, Medical imaging

The main objective of the study is to establish a recommended Phase 2 dose and schedule.

Key Points: 
  • The main objective of the study is to establish a recommended Phase 2 dose and schedule.
  • Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC).
  • Further details on the study can be found on Australian Clinical Trials , under identifier Ariceum SSO11O-01.
  • We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer.

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Retrieved on: 
Thursday, September 7, 2023
Carcinoma, Maintenance, EANM, PET, Cell, Immunotherapy, Doctor of Philosophy, SCLC, Neoplasm, Patient, Cancer, IB, Diagnosis, SST2, European Association of Urology, Therapy, Recurrence, Safety, Disease, Pharmaceutical industry, Vaccine, Medical imaging

The main objective of the study is to establish a recommended Phase 2 dose and schedule.

Key Points: 
  • The main objective of the study is to establish a recommended Phase 2 dose and schedule.
  • Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC).
  • Further details on the study can be found on Australian Clinical Trials , under identifier Ariceum SSO11O-01.
  • We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer.

NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress

Retrieved on: 
Tuesday, September 5, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, NETS, 18F, Half-life, EANM, PSMA, Survival, Cancer, Pharmacokinetics, University Hospital of Basel, FAP, Heterotrimeric G protein, Nuclear medicine, Radiopharmaceutical, Doctor of Philosophy, University Hospital of Zürich, Glomus tumor, European Association of Nuclear Medicine, Patient, PET/CT, Entrepreneurship, European Association for the Study of the Liver, Prostate cancer, Medical imaging

NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.

Key Points: 
  • NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.
  • The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation.
  • The programs are part of NUCLIDIUM’s comprehensive pipeline of copper-based radiotheranostics based on its flexible CuTraceTM platform.
  • The positive pre-clinical data for the diagnostic candidates from three of our programs and the preparation for clinical translation represent an important step for NUCLIDIUM.